Cresset Asset Management’s Editas Medicine EDIT Stock Holding History

Cresset Asset Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,969	Closed	-$238K	–	1029
2021 Q4	$238K	Sell	8,969 -18,805	-68%	-$647K	﹤0.01%	975
2021 Q3	$1.14M	Sell	27,774 -1,899	-6%	-$104K	0.02%	355
2021 Q2	$1.68M	Sell	29,673 -1,403	-5%	-$51.8K	0.02%	237
2021 Q1	$1.3M	Buy	31,076 +14,242	+85%	+$811K	0.02%	237
2020 Q4	$1.18M	Sell	16,834 -776	-4%	-$31.9K	0.02%	218
2020 Q3	$494K	Buy	17,610 +9,141	+108%	+$298K	0.01%	374
2020 Q2	$251K	Buy	+8,469	New	+$221K	0.01%	529

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Cresset Asset Management's EDIT Position: Q1 2022 in Review

Cresset Asset Management sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 8,969 shares — an estimated $238K sold.

Cresset Asset Management first reported a position in EDIT in Q2 2020 and held it in 7 quarters. The position peaked at $1.68M in Q2 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

Cresset Asset Management reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
Cresset Asset Management sold 8,969 Editas Medicine shares in Q1 2022, an estimated $238K.
Cresset Asset Management first reported a position in Editas Medicine in Q2 2020 and held it in 7 quarters.
Cresset Asset Management's Editas Medicine position peaked at $1.68M in Q2 2021.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on Cresset Asset Management's 13F filing for Q1 2022, filed 16 May 2022.